In its first in-licensing of a clinical compound, MorphoSys of Germany has obtained a worldwide exclusive licence to a monoclonal antibody in Phase I development from US-based Xencor.
In its first in-licensing of a clinical compound, MorphoSys of Germany has obtained a worldwide exclusive licence to a monoclonal antibody in Phase I development from US-based Xencor.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.
The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.
With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.
